/assets/production/practices/68edfd341efff207246df8bb02e1b404ebb28019/images/2698850.png)
Currently enrolling studies:
https://azneuroscienceresearch.com/
Email:
anr@centerforneurologyandspine.com
MOTRIC-CD Study for Cervical Dystonia (Study ID: NCT06830642)
This study is an oral, investigational treatment trial evaluating a new therapy for cervical dystonia in adult participants—no injections required.
About the Study:
Design: Participants complete a short eligibility form. If qualified, they enroll and begin treatment.
Treatment: Daily oral capsules taken at bedtime for 4 weeks (with a dose increase at mid-study). No injections.
Duration: Up to 18 weeks, broken down into:
12 weeks washout period from prior botulinum toxin injections (if applicable)
4 weeks of active treatment
2 weeks of safety follow-up
Visits: Approximately 5 clinic visits over the study duration. Some weekly check-ins may be done via phone; key visits—screening, treatment start, and follow-ups—must be in person, though additional in‑person visits are optional.
Placebo-Controlled: Participants may receive either the investigational oral medication or a placebo to assess efficacy vs. placebo.
Compensation & Cost:
All study-related care and procedures are provided at no cost.
Participants may be compensated for their time and travel (varies by site).
Eligibility:
Diagnosed with cervical dystonia
Currently using botulinum toxin injections with ongoing symptoms ("breakthrough symptoms")
Must be willing to pause injection therapy for at least 12 weeks prior to starting the study and may resume approximately 35 days after the treatment begins.
Sponsor:
Motric Bio
Trial Link: https://clinicaltrials.gov/study/NCT06830642
Click Here to Learn More:
Arizona Neuroscience Research is now enrolling participants in the MINT-C clinical trial, a Phase 3 study investigating Xeomin® (botulinum toxin type A) for the prevention of chronic migraine in adults.
About the Study:
This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized into 1 of 3 separate cohorts (1:1:1 randomization ratio, PIPE-307 Dose A: PIPE-307 Dose B: Placebo) for a total duration of approximately 30 weeks.
1. The subject is fluent in English.
2. Male or female 18 to 50 years of age, inclusive, at the first screening visit.
3. A diagnosis of relapsing-remitting multiple sclerosis (RRMS) according to the 2017 Revised McDonald Criteria.
Visits: Seven visits over approximately thirty-four weeks.
Enrollment: 168
Status: Open and Enrolling
Sponsor: Pipeline Therapeutics
https://clinicaltrials.gov/study/NCT06083753
https://www.nationalmssociety.org/news-and-magazine/news/ms-trial-alert-myelin-repair
2. Participants diagnosed with Relapsing forms of multiple sclerosis R(RMS) and satisfy the approved therapeutic indication for Bafiertam per the approved product labeling.
3. Participants may enroll if they are within 90 days of initiating therapy with Bafiertam.
Visits: Four visits over approximately 12 months (clinical and phone visits permitted).
Enrollment: 100
Status: Enrolling by Invitation
Sponsor: Banner Life Sciences
https://clinicaltrials.gov/study/NCT05978531
https://centerforneurologyandspine.com
This study is an oral, investigational treatment trial evaluating a new therapy for cervical dystonia in adult participants—no injections required.
About the Study:
Design: Participants complete a short eligibility form. If qualified, they enroll and begin treatment.
Treatment: Daily oral capsules taken at bedtime for 4 weeks (with a dose increase at mid-study). No injections.
Duration: Up to 18 weeks, broken down into:
12 weeks washout period from prior botulinum toxin injections (if applicable)
4 weeks of active treatment
2 weeks of safety follow-up
Visits: Approximately 5 clinic visits over the study duration. Some weekly check-ins may be done via phone; key visits—screening, treatment start, and follow-ups—must be in person, though additional in‑person visits are optional.
Placebo-Controlled: Participants may receive either the investigational oral medication or a placebo to assess efficacy vs. placebo.
Compensation & Cost:
All study-related care and procedures are provided at no cost.
Participants may be compensated for their time and travel (varies by site).
Eligibility:
Diagnosed with cervical dystonia
Currently using botulinum toxin injections with ongoing symptoms ("breakthrough symptoms")
Must be willing to pause injection therapy for at least 12 weeks prior to starting the study and may resume approximately 35 days after the treatment begins.
Sponsor:
Motric Bio
Trial Link: https://clinicaltrials.gov/study/NCT06830642
Click Here to Learn More:
MINT-E Study for Episodic Migraine (Study ID: M602011085)
Arizona Neuroscience Research is now enrolling participants in the MINT-C clinical trial, a Phase 3 study investigating Xeomin® (botulinum toxin type A) for the prevention of chronic migraine in adults.
About the Study:
This randomized, placebo-controlled trial evaluates whether Xeomin can reduce the number of migraine days experienced by participants. All qualified participants will receive Xeomin at some point during the study.
Duration: Up to 1 year
Visits: 14 total (including 8 remote telehealth visits)
Treatment: 4 injection sessions every 12 weeks
Compensation: Study-related care and medication provided at no costEligibility:
Age 18 or older
Diagnosed with Episodic migraine
Migraines began before age 50
Sponsor:
Merz Therapeutics GmbH
Trial Link: https://clinicaltrials.gov/study/NCT07018713
Click Here to Learn More: MINT-E - Arizona Neuroscience Research
MINT-C Study for Chronic Migraine (Study ID: M602011084)
Arizona Neuroscience Research is now enrolling participants in the MINT-C clinical trial, a Phase 3 study investigating Xeomin® (botulinum toxin type A) for the prevention of chronic migraine in adults.
About the Study:
This randomized, placebo-controlled trial evaluates whether Xeomin can reduce the number of migraine days experienced by participants. All qualified participants will receive Xeomin at some point during the study.
Duration: Up to 1 year
Visits: 14 total (including 8 remote telehealth visits)
Treatment: 4 injection sessions every 12 weeks
Compensation: Study-related care and medication provided at no costEligibility:
Age 18 or older
Diagnosed with Episodic migraine
Migraines began before age 50
Sponsor:
Merz Therapeutics GmbH
Trial Link: https://clinicaltrials.gov/study/NCT07018713
Click Here to Learn More: MINT-E - Arizona Neuroscience Research
MINT-C Study for Chronic Migraine (Study ID: M602011084)
About the Study:
This randomized, placebo-controlled trial evaluates whether Xeomin can reduce the number of migraine days experienced by participants. All qualified participants will receive Xeomin at some point during the study.
Duration: Up to 1 year
Visits: 14 total (including 8 remote telehealth visits)
Treatment: 4 injection sessions every 12 weeks
Compensation: Study-related care and medication provided at no costEligibility:
Age 18 or older
Diagnosed with chronic migraine
Migraines began before age 50
Sponsor:
Merz Therapeutics GmbH
Trial Link: https://clinicaltrials.gov/study/NCT07018713
Click here to Learn More: MINT-C - Arizona Neuroscience Research
Cenobamate Monotherapy in Adults with Partial-Onset Seizures (YKP3089C049)
This is a multicenter, open-label study evaluating the safety and efficacy of Cenobamate as monotherapy in adults with newly diagnosed or recurrent partial-onset seizures.
Duration: Up to 1 year
Visits: 14 total (including 8 remote telehealth visits)
Treatment: 4 injection sessions every 12 weeks
Compensation: Study-related care and medication provided at no costEligibility:
Age 18 or older
Diagnosed with chronic migraine
Migraines began before age 50
Sponsor:
Merz Therapeutics GmbH
Trial Link: https://clinicaltrials.gov/study/NCT07018713
Click here to Learn More: MINT-C - Arizona Neuroscience Research
Cenobamate Monotherapy in Adults with Partial-Onset Seizures (YKP3089C049)
This is a multicenter, open-label study evaluating the safety and efficacy of Cenobamate as monotherapy in adults with newly diagnosed or recurrent partial-onset seizures.
Eligibility:
Adults aged 18 years and older.
Diagnosed with partial-onset seizures.
Currently not on any antiepileptic drugs or willing to transition to monotherapy.Study Details:
Visits: Participants will undergo an initial screening, followed by regular visits throughout the treatment period for monitoring and assessments.
Status: Open and enrolling.
Sponsor: SK Life Science, Inc.
Website: Cenobamate Monotherapy Study | SK Life Science
Learn More: https://clinicaltrials.gov/study/NCT04513860
Adults aged 18 years and older.
Diagnosed with partial-onset seizures.
Currently not on any antiepileptic drugs or willing to transition to monotherapy.Study Details:
Visits: Participants will undergo an initial screening, followed by regular visits throughout the treatment period for monitoring and assessments.
Status: Open and enrolling.
Sponsor: SK Life Science, Inc.
Website: Cenobamate Monotherapy Study | SK Life Science
Learn More: https://clinicaltrials.gov/study/NCT04513860
Eligibility:
Age: 18–75 years old
Currently experiencing focal onset seizures
Taking one or more anti-seizure medications
Study Details:
Visits: Up to 9 weeks of screening, 12 weeks of treatment, and 2 weeks of follow-up. Most visits can be completed from home, with only 2 in-office visits required in some cases.
Enrollment: 400 participants
Status: Open and enrolling
Sponsor: Praxis Precision Medicines
https://power1study.com/
Age: 18–75 years old
Currently experiencing focal onset seizures
Taking one or more anti-seizure medications
Study Details:
Visits: Up to 9 weeks of screening, 12 weeks of treatment, and 2 weeks of follow-up. Most visits can be completed from home, with only 2 in-office visits required in some cases.
Enrollment: 400 participants
Status: Open and enrolling
Sponsor: Praxis Precision Medicines
https://power1study.com/
This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis
Eligibility:
Age: 18–60 years old
Primary progressive MS or secondary progressive MS without relapses
Meet criteria for neuromyelitis optica spectrum disorder
Relapse in the 30 days prior to randomization
≥ 10 years disease duration from onset with patient's EDSS ≤ 2.0 (patient reported is adequate in absence of written medical record)
An EDSS of ≤ 5.5 at the Screening Visit
Must have documentation of:
at least 1 relapse within the previous year OR
≥ 2 relapses within the past 2 years OR
≥ 1 active Gd-enhancing brain lesion on an MRI scan within the past 6 months prior to screening
Not of childbearing potential or willing to follow contraceptive guidance Has > 20 Gd+ lesions on brain MRI at screening
Study Details:
Visits: 52 weeks total, not exceeding 92 weeks.
Screening: At least 1 clinic visit for health checks and tests to determine eligibility.
Study Treatment Period Part A: Participants are randomly assigned to receive obexelimab (67% chance) or placebo (33% chance). Weekly visits include health checks, tests, and treatment administration.
Study Treatment Period Part B: All participants receive obexelimab (no placebo).
Follow-up Period: 1 clinic visit 12 weeks after the Week 24 visit (or the last Study Treatment Visit).
Enrollment: 93
Status: Open and enrolling
Sponsor: Zenas BioPharma (USA)
https://themoonstonestudy.com/
Eligibility:
Age: 18–60 years old
Primary progressive MS or secondary progressive MS without relapses
Meet criteria for neuromyelitis optica spectrum disorder
Relapse in the 30 days prior to randomization
≥ 10 years disease duration from onset with patient's EDSS ≤ 2.0 (patient reported is adequate in absence of written medical record)
An EDSS of ≤ 5.5 at the Screening Visit
Must have documentation of:
at least 1 relapse within the previous year OR
≥ 2 relapses within the past 2 years OR
≥ 1 active Gd-enhancing brain lesion on an MRI scan within the past 6 months prior to screening
Not of childbearing potential or willing to follow contraceptive guidance Has > 20 Gd+ lesions on brain MRI at screening
Study Details:
Visits: 52 weeks total, not exceeding 92 weeks.
Screening: At least 1 clinic visit for health checks and tests to determine eligibility.
Study Treatment Period Part A: Participants are randomly assigned to receive obexelimab (67% chance) or placebo (33% chance). Weekly visits include health checks, tests, and treatment administration.
Study Treatment Period Part B: All participants receive obexelimab (no placebo).
Follow-up Period: 1 clinic visit 12 weeks after the Week 24 visit (or the last Study Treatment Visit).
Enrollment: 93
Status: Open and enrolling
Sponsor: Zenas BioPharma (USA)
https://themoonstonestudy.com/
Relapse Remitting Multiple Sclerosis (PTI-307-201 VISTA)
Multiple sclerosis (MS) is a chronic neurological disease characterized by inflammatory demyelination that results in the disruption of neuronal transmission and ultimately neurodegeneration and progressive disability. RRMS is defined by attacks or relapses of new MS symptoms.
Multiple sclerosis (MS) is a chronic neurological disease characterized by inflammatory demyelination that results in the disruption of neuronal transmission and ultimately neurodegeneration and progressive disability. RRMS is defined by attacks or relapses of new MS symptoms.
This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized into 1 of 3 separate cohorts (1:1:1 randomization ratio, PIPE-307 Dose A: PIPE-307 Dose B: Placebo) for a total duration of approximately 30 weeks.
1. The subject is fluent in English.
2. Male or female 18 to 50 years of age, inclusive, at the first screening visit.
3. A diagnosis of relapsing-remitting multiple sclerosis (RRMS) according to the 2017 Revised McDonald Criteria.
Visits: Seven visits over approximately thirty-four weeks.
Enrollment: 168
Status: Open and Enrolling
Sponsor: Pipeline Therapeutics
https://clinicaltrials.gov/study/NCT06083753
https://www.nationalmssociety.org/news-and-magazine/news/ms-trial-alert-myelin-repair
Relapse Remitting Multiple Sclerosis (COMB157GUS09 SOSTOS)
This study will evaluate if relapsing-remitting MS patients who have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy.
Age 18-45
Visits: Thirteen visits over approximately twenty-one months plus 1 week for screening.
Enrollment: 150
Status: Open and Enrolling
Sponsor: Novartis
https://clinicaltrials.gov/study/NCT05090371
Visits: Thirteen visits over approximately twenty-one months plus 1 week for screening.
Enrollment: 150
Status: Open and Enrolling
Sponsor: Novartis
https://clinicaltrials.gov/study/NCT05090371
Relapse Remitting Multiple Sclerosis (BLS-11-404 SIMPLE)
This is a Prospective, Observational Study of Bafiertam Evaluating Persistence on Treatment, Safety, Tolerability, And Effectiveness In Routine Clinical Practice.
Adult participants with a diagnosis of RRMS who have been receiving continuous treatment with Bafiertam monotherapy per the approved product label for no more than 3 months (90 days) are eligible to enroll in the study. Their satisfaction with Bafiertam treatment will be assessed using a 9-Item Treatment Satisfaction Questionnaire for Medication (TSQM-9). Patients are to be included in the study.
1. Male or non-pregnant female aged 18 years and older.2. Participants diagnosed with Relapsing forms of multiple sclerosis R(RMS) and satisfy the approved therapeutic indication for Bafiertam per the approved product labeling.
3. Participants may enroll if they are within 90 days of initiating therapy with Bafiertam.
Visits: Four visits over approximately 12 months (clinical and phone visits permitted).
Enrollment: 100
Status: Enrolling by Invitation
Sponsor: Banner Life Sciences
https://clinicaltrials.gov/study/NCT05978531
https://centerforneurologyandspine.com
REMODEL 2
A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of remibrutinib vs. teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib
Age 18-55 years old
One documented clinical relapse within 12 months or at least two documented relapses within the last 2 years OR the presence of at least one T1Gd+ lesion on MRI in the last 12 months
https://azneuroscienceresearch.com/
(#308) Essential Tremor (JZP385-201)
A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of remibrutinib vs. teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib
Age 18-55 years old
One documented clinical relapse within 12 months or at least two documented relapses within the last 2 years OR the presence of at least one T1Gd+ lesion on MRI in the last 12 months
- Visits: 13 study visits over approximately 2.5 years, with a visit about every 3 months
- Enrollment: 800 participants
- Status: Upcoming enrollment
- Sponsor: Novartis
https://azneuroscienceresearch.com/
(#308) Essential Tremor (JZP385-201)
Treatment of Adults With Moderate to Severe Essential Tremor: Essential tremor (ET) is a neurological disorder that causes your hands, head, trunk, voice or legs to shake rhythmically.
- Participant must be 18 to 80 years of age inclusive, at the time of signing the informed consent.\
/assets/production/practices/68edfd341efff207246df8bb02e1b404ebb28019/images/2698825.jpg)
https://clinicaltrials.gov/study/NCT05122650
(#237) Relapse Remitting Multiple Sclerosis (PTI-307-201 VISTA)
- Subject is fluent in English.
- Male or female 18 to 50 years of age, inclusive, at the first Screening visit.
- A diagnosis of relapsing-remitting multiple sclerosis (RRMS) according to the 2017 Revised McDonald Criteria.
/assets/production/practices/68edfd341efff207246df8bb02e1b404ebb28019/images/2698829.jpg)
https://clinicaltrials.gov/study/NCT06083753?term=PIPE-307&rank=2
(#196) Relapse Remitting Multiple Sclerosis (COMB157GUS09 SOSTOS)
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab (KESIMPTA) versus staying on their continued current therapy.
- Age 18-45 years
- Diagnosis of RRMS per McDonald Criteria (2017)
- EDSS 0-5.5 (Inclusive)
- Able to obtain MRI and attend study visits at sites
- Willing to use wearable device as specified in the protocol
- Able to provide blood sample
- On a current DMT with approved label use for treatment of RRMS at least 6 months prior to Screening
- No relapse reported within 6 months prior to Screening
- Patients may enroll in the trial if they have subclinical disease activity as measured by MRI prior to enrollment. An absence of MRI activity is not exclusionary.
/assets/production/practices/68edfd341efff207246df8bb02e1b404ebb28019/images/2698831.jpg)
https://clinicaltrials.gov/study/NCT05090371
(#384) Relapse Remitting Multiple Sclerosis (BLS-11-404 SIMPLE)
Adult participants with a diagnosis of RRMS who have been receiving continuous treatment with Bafiertam monotherapy per the approved product label for no more than 3 months (90 days) are eligible to enroll in the study. Their satisfaction with Bafiertam treatment will be assessed using a 9-Item Treatment Satisfaction Questionnaire for Medication (TSQM-9). To be included in the study, patients.
- Male or non-pregnant female aged 18 years and older.
- Participants diagnosed with Relapsing forms of multiple sclerosis R(RMS) and satisfy the approved therapeutic indication for Bafiertam per the approved product labeling.
- Participants may enroll if they are within 90 days of initiating therapy with Bafiertam.
/assets/production/practices/68edfd341efff207246df8bb02e1b404ebb28019/images/2698834.jpg)
https://clinicaltrials.gov/study/NCT05978531
https://azneuroscienceresearch.com/